July 7, 2018 - Patient Worthy

ICYMI: Orphan Drug Designation Has Been Awarded to a Drug Being Developed to Treat Sickle Cell Disease

Post author:Anna Hewitt
Post published:July 7, 2018
Post category:Sickle Cell Disease

The experimental drug olinciguat (IW-1701) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of sickle cell disease. The full article can…

stux / Pixabay

A Hospital in Colorado Will Take Part in a Cystic Fibrosis Phase 3 Trial

Post author:Anna Hewitt
Post published:July 7, 2018
Post category:Cystic Fibrosis

The Children’s Hospital Colorado has announced that it will part in a Phase 3 clinical trial for an experimental new cystic fibrosis therapy. The full article can be found at…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

ICYMI: Orphan Drug Designation Has Been Awarded to a Drug Being Developed to Treat Sickle Cell Disease

A Hospital in Colorado Will Take Part in a Cystic Fibrosis Phase 3 Trial

The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

“Shades of Psoriasis”: Plaque Psoriasis and Sharing Your Story

Understanding RSV: Why Combatting Ethnic and Age-Related Health Disparities Could Improve Outcomes

We Need Equity and Diversity Within Rare Disease Research

DNA in Color: How Ronya Nelson is Working to Close the Diversity Gap in Genetics - Part 1

Bridging the Diversity Gap in Healthcare

Congratulations to the 2023 Recipients of the Diversity in Lupus Research Awards!

Welcome to Study of the Week. We go in-depth and select a study we think is of particular interest, discussing details, explaining its importance, who may be impacted and lots more!

Let’s Work Together!

Keep Up to Date

Learn More